Floatz logo

Pembrolizumab

Metastatic Pancreatic Adenocarcinoma

Mayo Clinicmonoclonal_antibodyPhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Metastatic Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Olaparib
Lantern Pharma Inc.
Phase 3BB
Epirubicin
Minia University
Phase 3BB
Irinotecan Sucrosofate
SWOG Cancer Research Network
Phase 3BB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
bkt140
Gulam Manji
Phase 2BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →